rilpivirine hydrochloride · Janssen Prods · NDA 219016
Edurant Ped
Earliest generic entry, as listed
23 Oct 2037
Blocked by patent: US 11065198.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11065198 | product | 23 Oct 2037 |
Exclusivities · 2 unexpired
| PED | pediatric (6 months added) | 15 Sep 2027 |
| NP | new product | 15 Mar 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219016 · 001 · RLD | tablet, for suspension, oral | EQ 2.5MG BASE | 23 Oct 2037 |